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Abstract  
 
Microglia are the resident innate immune cells in the central nervous system (CNS), 
representing the first defense line of the neural parenchyma. However, its chronic activation is 
implicated in neurodegenerative disorders by the uncontrolled release of diverse molecular 
mediators such as inflammatory cytokines. 
Among all dietary phytochemicals, polyphenols are the major anti-inflammatory 
molecules provided by some plants. As example, raspberries are an enriched natural source 
of polyphenols such as ellagic acid, flavanols; and phenolic acids. However, digestion strongly 
modifies the structure of polyphenols, producing metabolites with different bioactivities. Thus, 
it is imperative the study of digested polyphenols for a better elucidation about their effects.  
The main goal of this study was to evaluate the bioactivity of raspberry polyphenols as 
neuroinflammatory attenuators. The fractions studied were composed by polyphenols that are 
bioaccessible to blood serum, obtained from in vitro digestion of five different quasi-isogenic 
raspberries. Furthermore, N9 murine microglial cell line was implemented as model of 
neuroinflammation and the range of non-cytotoxic concentrations of each fraction was 
determined. Then, the neuroinflammatory attenuation induced by each digested fraction in 
LPS-stimulated microglia was evaluated and compared. As result, some of the fractions 
attenuated microglial pro-inflammatory activation, significantly decreasing the expression of 
membrane protein CD-40 (marker of microglial activation) and the production of the pro-
inflammatory markers, nitric oxide (NO), tumor necrosis factor-α (TNF-α) and intracellular 
superoxide (O2•-). 
Additionally, a yeast model of inflammation was used as a mechanistic tool to elucidate 
the molecular mechanisms underlying the anti-inflammatory activity of the digested raspberry 
fractions. The results showed that these compounds inhibit the yeast Crz1/calcineurin 
pathway, which is homologous to the mammalian nuclear factor of activated T-cells 
(NFAT)/calcineurin, suggesting that they may prevent microglial neuroinflammation through 
this pathway. 
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Resumo  
 
 Quando exposto a diversas agressões tais como infeções, toxinas ou traumatismos, o 
sistema nervoso central medeia uma resposta inflamatória complexa e ao mesmo tempo 
dinâmica. Esta resposta inclui uma curta e eficiente ativação do sistema imunitário, que 
geralmente é mediada pela população de células imunitárias residentes – a microglia. 
 A microglia representa cerca de 12% do tecido cerebral e participa na primeira linha 
de defesa do parênquima neural. Num estado não ativado apresenta uma morfologia 
ramificada, tendo como função a continua monitorização do espaço que rodeia os neurónios. 
Uma vez exposta a um estímulo pro-inflamatório, a microglia entra num estado ativado que, 
tipicamente, é acompanhado de uma transição da morfologia para uma forma ameboide, o 
que favorece a fagocitose. Neste estado, a expressão de muitos recetores de superfície 
relacionados com a resposta imunitária é aumentada. São também induzidas muitas vias de 
sinalização celular que conduzem à secreção de diferentes compostos pro-inflamatórios. Por 
exemplo, compostos como o fator de necrose tumoral – α (TNF-α), a interleucina - 1β (IL-1β), 
ou as espécies reativas de oxigénio, são regulados por diferentes vias de sinalização celular 
tais como a via do fator nuclear – κB (NF-κB), a via do fator nuclear das células T ativadas 
(NFAT) ou a vias das cinases MAP (MAPK). 
 Muitos dos agentes pró-inflamatórios conhecidos e descritos são pesticidas como o 
paraquato, dieldrina, lindano ou rotenona; outros são toxinas como os lipopolissacarídeos 
(LPS) provenientes da membrana exterior de bactérias gram-negativas. Geralmente, estes 
agentes estão associados a casos patológicos, nos quais a microglia adquire um estado de 
sobreativação crónica. Nestes casos, muitos compostos mediadores da inflamação são 
continuamente e abundantemente secretados pela microglia, causando lesões e prococando 
ativação das vias de apoptose nas células neuronais vizinhas. Elevados e contínuos níveis de 
produção de óxido nítrico, de espécies reativas de oxigénio e de citocinas estão descritos 
como patológicos em várias doenças neurodegenerativas, tais como Alzheimer, Parkinson, 
Huntington, Esclerose Múltipla ou Esclerose lateral amiotrófica. Por sua vez, proteínas como 
a α-sinucleína ou a β-amilóide, que estão descritas nas doenças de Parkinson e Alzheimer, 
respetivamente, atuam como agentes pro-inflamatórios, perpetuando e intensificando a 
resposta inflamatória. Nos casos mais severos, ocorre uma fragilização da barreira 
hematoencefálica, o que permite a entrada de macrófagos periféricos para a progressão e 
intensificação do processo inflamatório. 
 Os hábitos alimentares atuais também promovem uma ação pró-inflamatória que 
contribui para a progressão de algumas das doenças crónicas anteriormente citadas. A dieta 
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atual envolve o elevado consumo de carnes vermelhas, doces, alimentos ricos em gorduras 
e bebidas gaseificadas, enquanto há um baixo consumo de fruta fresca, nozes, vegetais, 
cereais e fontes naturais de ómega-3 como o peixe. 
Muitos estudos com vista à atenuação da neuroinflamação comprovaram que a dieta, 
e em especial, o consumo de algumas classes de polifenóis provenientes da fruta e dos 
vegetais, parece ter um efeito positivo nesse contexto. No entanto, é importante mimetizar os 
diversos processos de transformação que ocorrem nos polifenóis durante a digestão in vivo, 
uma vez que essas transformações alteram drasticamente a sua função biológica. Uma das 
formas de mimetizar a digestão é o recurso à utilização de modelos de digestão in vitro, a 
partir dos quais se obtêm as frações digeridas dos polifenóis. Os metabolitos constituintes 
destas frações são semelhantes àqueles que estariam bioacessíveis às células alvo in vivo. 
A procura de polifenóis cujos efeitos sejam benéficos face às mais diversas patologias, 
como o cancro ou as doenças neurodegenerativas, levou ao aumento do estudo dos 
pequenos frutos. Estes frutos possuem uma vasta gama e um elevado teor em polifenóis, o 
que propicia a sua utilização na investigação científica. Em particular, as espécies do género 
Rubus têm sido referenciadas como altamente benéficas para a saúde. 
 No presente estudo, avaliou-se a eventual atenuação da neuroinflamação promovida 
por cinco frações digeridas de diferentes framboesas em células de microglia. As cinco 
cultivares de framboesa utilizadas provêm de um banco de germoplasma do James Hutton 
Institute, caracterizando-se por diferirem entre si na constituição nas diferentes classes de 
polifenóis. Para a obtenção das frações digeridas, as diferentes framboesas quasi-isogénicas 
foram liofilizadas, solubilizadas em água e submetidas a um modelo de digestão in vitro. De 
cada tipo de framboesa resultaram duas frações distintas, uma fração digerida bioacessível 
ao cólon e uma fração digerida bioacessível ao soro do sangue. Para o presente trabalho 
apenas foram utilizadas as frações bioacessíveis ao soro do sangue. Todo o processo da 
digestão in vitro até à obtenção das frações foi desenvolvido pelo Dr. Derek Stewart, do James 
Hutton Institute. 
A primeira tarefa deste trabalho foi a implementação do modelo de neuroinflamação 
com a linha celular N9 de microglia de ratinho. Para tal, as células foram estabelecidas em 
cultura in vitro e estimuladas com LPS. Devido à complexidade inerente à resposta 
inflamatória mediada pela microglia, foi necessário identificar e aceder a diferentes 
marcadores pró-inflamatórios típicos da microglia ativada, através de diferentes técnicas. Para 
a determinação do óxido nítrico libertado pelas células, foi quantificado o teor em nitritos no 
meio de cultura através da reação de Griess. O fator de necrose tumoral – α (TNF-α) foi 
quantificado no meio de cultura, recorrendo à técnica de Enzyme Linked Immuno Sorbent 
Assay (ELISA) quantitativa. O radical superóxido e a proteína de membrana CD-40 foram 
ambos quantificados recorrendo à técnica de citometria de fluxo. 
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A tarefa seguinte foi a avaliação da citotoxicidade das frações de framboesa digerida, 
como forma de determinar, dentro da gama de concentrações descritas como fisiológicas, 
quais as concentrações não toxicas adequadas para a sua utilização na linha celular N9 de 
microglia de ratinho. 
 A última tarefa foi a avaliação da atenuação da neuroinflamação promovida pelas 
frações digeridas na linha celular N9 de microglia de ratinho. Para tal, as células foram pré-
incubadas com as diferentes frações digeridas de framboesa e seguidamente estimuladas 
com LPS. De seguida, foram quantificados os diferentes marcadores previamente validados 
na primeira tarefa (óxido nítrico, TNF-α, CD-40 e radical superóxido). Como resultado, três 
das frações digeridas revelaram grande consistência na significativa redução da produção e 
expressão dos diversos marcadores na linha de microglia N9, o que evidência o seu forte 
contributo para a atenuação da neuroinflamação. Por outro lado, as restantes duas frações 
não exibiram um efeito anti-inflamatório consistente para todos os marcadores inflamatórios, 
sendo que em alguns desses marcadores não se observaram reduções significativas na 
produção/expressão relativamente aos controlos positivos da inflamação. 
Adicionalmente, como ferramenta mecanística foi utilizado um modelo de inflamação 
construído em levedura. A utilização deste modelo revelou que, de alguma forma, os 
metabolitos presentes nas frações de framboesa digerida interferem na regulação da via 
celular calcineurina / Crz1, reprimindo a sua indução pelo dicatião cálcio (Ca2+). Esta via de 
sinalização é regulada de uma forma semelhante nos mamíferos, sendo que CRZ1 é ortólogo 
de NFAT, que, por sua vez, está intrinsecamente relacionado com a inflamação. Assim, os 
resultados obtidos com o modelo de inflamação em levedura sugerem que uma das vias pela 
qual os metabolitos presentes nas frações digeridas de framboesa atenuam a 
neuroinflamação na microglia é pela via da calcineurina - NFAT. 
Por último, os resultados da atenuação da inflamação na microglia e nos ensaios em 
levedura foram comparados com as diferentes composições químicas em polifenóis de cada 
uma das frações digeridas utilizadas. Por conseguinte, algumas classes de polifenóis, tais 
como os conjugados de ácido elágico, foram identificadas como relacionadas com o poder 
anti-inflamatório das frações. 
 
 
 
 
 
Palavras-chave 
Polifenóis, framboesa, quasi-isogénicas, digestão in vitro, atenuação da neuroinflamação  
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1. Objectives  
 
 Neuroinflammation can be initiated in response to a variety of injuries, including 
infection, traumatic brain injury or toxic metabolites1. In the central nervous system, including 
the brain and spinal cord, microglia are the resident innate immune cells that mediate the 
inflammatory response to these injuries1. 
 In the present study, the main objective was the evaluation of the neuroinflammatory 
attenuation that comes from the treatment with five different digested quasi-isogenic raspberry 
fractions. These fractions were obtained from the in vitro digestion of germplasm raspberry 
lines, in James Hutton Institute. 
 The first task was the implementation of N9 murine microglial cell line as a model of 
neuroinflammation, by accessing diverse pro-inflammatory and activation markers typical of 
LPS-stimulated microglia. Different techniques such as ELISA, griess reaction, flow cytometry 
and western blot were used for that purpose. Secondly, the cytotoxicity of the digested 
raspberry polyphenolic fractions was assayed in order to guarantee the range of non-toxic 
concentrations while using also physiological concentrations. 
 As the final task, the inflammatory attenuation from the treatment with each fraction in 
LPS-stimulated microglia was evaluated by the analysis of the markers previously validated in 
the model implementation. Also, a yeast model of inflammation was used as mechanistic tool 
for the evaluation of the anti-inflammatory bioactivity of the digested raspberry fractions as 
inhibiters of Crz1/calcineurin pathway.   
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2. Theoretical fundaments 
 
2.1. Microglia: the innate immune cell of central nervous system 
 Microglia are the resident innate immune cells in the central nervous system (CNS) and 
comprise approximately 12% of the brain tissue2. They are involved in the first defense line for 
the neural parenchyma, releasing diverse molecular mediators such as inflammatory 
cytokines.  
 Generally, it is accepted that the original microglia population differentiates from cells 
of the myeloid lineage, which occurs in early embryonic development. This could justify the 
common expression of the majority of surface markers of monocytes and macrophages: CD1a, 
CD2, CD4, CD16, CD18, CD40, CD45, major histocompatibility complex (MHC) class I and II, 
among many others3. 
Microglia can vary between two different 
morphological phenotypes: ramified, characteristic in 
cells unexposed to inflammatory triggers (surveillant 
cells); and amoeboid, the typical physiology of cells 
reacting to inflammatory triggers (activated cells)4 
(Figure 1). Ramified cells are constantly surveying the 
surrounding environment with their retractile processes 
and their cell bodies are spaced within the CNS, avoiding 
overlap5. At this “resting” state, several key surface 
receptors involved in the innate immune response are 
expressed at low levels, such as MHC molecules6; CD45 
(the leucocyte common antigen)7 and CD-11b8. In 
addition, cell surface receptor-ligands, such as, CD-200 are present, contributing to 
maintenance of neuron-microglia communication in the CNS9. 
 Once exposed to pro-inflammatory triggers such as pathogens, brain injuries, dead or 
dying cells and immunological stimuli, microglia cells respond by modifying its ramified 
morphology to the amoeboid shape, favoring phagocytic activity10. These alterations are also 
followed by changes in signaling cascades, which promote upregulation in the expression of 
many cell surface receptors, as well an increase in the production of other pro-inflammatory 
mediators11, 12. As example, the release of tumor necrosis factor-alpha (TNF-α) is also a 
reliable marker of microglial activation13, 14. 
Although, during the development of some neurodegenerative disorders, microglia is 
reported to acquire a prejudicial overactivated stage that persists chronically. At this stage, the 
continuous high release of many of the pro-inflammatory mediators such as cytokines15, 16, 
Figure 1 – Microglia are morphologically 
and functionally dynamic cells. They are 
able to change from highly ramified shapes 
(non-activated cells) to completely lacking 
processes cellular bodies (activated cells)4.  
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reactive oxygen species (ROS)17 or nitric oxide (NO)18 are described as implicated in the 
pathology of Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease, 
Multiple sclerosis, Amyotrophic lateral sclerosis and other neurodegenerative disorders. In 
addition, those mediators can also strongly contribute for cerebrovascular damage in diverse 
neurodegenerative disorders such as AD and PD19.  
 
2.2. Neuroinflammation 
 The CNS mediates a dynamic immune and inflammatory response when exposed to 
infections, trauma, stroke, toxins and other stimuli capable of inducing an activation of the 
innate immune system. This response is usually mediated by microglial activation. 
Notwithstanding, microglial activation can have either positive or detrimental effects on 
neurons, according to the duration and amounts of cytokines and growth factors secreted20. 
 Within activation, microglia produce inflammatory mediators that are essential to 
protect the CNS against injuries. Also, damaged or dead cells increase the phagocytic activity 
of activated microglia21. However, it is typically a short-lived activation with no harmful effects 
for other neuronal cells. It is believed that this acute microglial activation is beneficial for CNS, 
contributing for host protection and tissue repair22. 
 On the other hand, chronic neuroinflammation persists long time after the initial injury 
or trigger and it is often a self-perpetuating event. Many pro-inflammatory mediators such as 
cytokines are highly increased and sustained15. Also, it occurs a notable augmentation of 
oxidative and nitrosative stress that persists chronically, injuring surrounding neuronal cells 
and promoting diverse neurodegenerative disorders23.  
 With chronic and sustained 
states of neuroinflammation, there is 
commonly a compromise of the blood 
brain barrier (BBB) which increases 
infiltration of peripheral macrophages 
into the brain neural parenchyma to 
further perpetuate the inflammation24  
(Figure 2). 
 Whether neuroinflammation is 
beneficial or harmful to the brain, 
critically depends on the duration and 
intensity of the inflammatory 
response25, 26. 
Figure 2 – Schematic representation of the neurovascular unit that 
constitutes the Blood-brain barrier (BBB). Vascular endothelial cells 
form the blood vessel and associate with astrocyte and pericytes 
forming the basal lamina. Other components of the neurovascular 
unit are neurons and microglia. Macrophages can also infiltrate 
during severe neuroinflammatory events. Figure adapted from C. L. 
Willis, Toxicol Pathol 39, 172 (2011). 
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2.2.1 – Markers of microglial activation  
 Because microglial activation is a complex and dynamic process, it is not simple to 
identify and conjugate the different molecular players. However, several pathways27-29 are 
implicated and some resultant molecules are described as reliable activation markers.  
 Nuclear factor kappa B (NF-κB) pathway 
Nuclear factor kappa B (NF-κB) is a transcription factor that regulates the expression 
of inducers and effectors at many points in the complex networks related to the response to 
pathogens30, 31. However, this protein extends its transcriptional regulation of the immune 
response, by influencing also gene expression pathways that impact cell survival, 
differentiation and proliferation. Because of these wide spectrum implications, the 
dysregulation of NF-κB is normally described in various pathological situations, including 
neuroinflammatory disorders32-34. 
The NF-κB dimers are present in the cytoplasm in an inactive state, sequestered by 
inhibitory IκB proteins, which mask the nuclear localization signals (NLS). The activation 
process of this transcriptional factor is mediated by the IκB kinase (IKK) complex. When 
activated by pro-inflammatory stimulus, such as lipopolysaccharide (LPS)35, ROS36, TNFα37 or 
interleukin 1-beta (IL-1β)38, the IKK complex promote phosphorylation and degradation of IκB 
proteins and subsequent release and activation of NF-κB39. Then, NF-κB activation does not 
require protein synthesis, once the interaction with diverse pro-inflammatory mediators can 
directly induce the activity of this transcription factor.  
 Nuclear factor of activated T cells (NFAT) pathway 
NFAT is a DNA binding protein required for pro-inflammatory gene expression, which 
is modulated by calcineurin phosphatase activity40. 
In its phosphorylated state, NFAT localizes to the 
cytoplasm, where it remains inactive. Once 
stimulated, calcineurin dephosphorylates cytosolic 
NFAT allowing it’s translocation to the nucleus 
where it binds promoters that activate transcription 
of a large number of genes during an effective 
immune response41, 42(Figure 3). Despite the close 
involvement of NFAT in the course of pro-
inflammatory events, recent findings confirmed 
also that this transcription factor regulates 
microglial phenotype, as well as the expression of 
TNF-α and MCP-127 . 
Figure 3 - The Calcineurin-NFAT signalling 
pathway. Increase in the intracellular calcium 
activates the cellular phosphatase Calcineurin (CN) 
through interaction with Calmodulin (CaM). 
Activated CN dephosphorylates NFAT, allowing it’s 
translocation for the nucleus were it binds to the 
promoters of pro-inflammatory genes. Adapted 
from: (http://www.angiobodies.com/figuras/uam_fig2.gif) 
Pro-inflammatory 
genes 
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 Mitogen-activated protein kinases (MAPK) pathway 
 Mitogen-activated protein kinases (MAPK) contitute a family of 
serine/threonine/tyrosine-specific protein kinases. These proteins modulate cellular response 
to diverse external stimuli, such as osmotic stress, heat shock, pro-inflammatory cytokines or 
LPS. In the CNS, this cellular response in usually mediated by microglia43, 44.  
 Generally, MAPK proteins form a chain of proteins that transduce signals from a cellular 
surface receptor to the DNA in the nucleus. When the receptor on the cell membrane binds to 
a signaling molecule, a signal is produced and redirected to the nucleus via MAPKs which 
communicate by adding phosphate groups to a neighboring protein. The pathway culminates 
with the signal reaching the nucleus, triggering the expression of proteins that specifically 
promote alterations in the cell, such as mitosis or inflammatory response. 
 Nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) pathway 
NADPH oxidase is a membrane-bound enzyme that catalyzes the production of 
superoxide from oxygen in response to various stimuli, including pathogen-associated 
molecular patterns (PAMPs), inflammatory peptides45 and multiple neurotoxins46. Superoxide 
aims to eliminate bacteria and fungi, mainly by interrupting their metabolic activity and 
promoting lipid peroxidation. This radical can spontaneously produce hydrogen peroxide that 
is submitted to further reactions, generating additional ROS. This also represents the main 
mechanism through which microglia produce neurotoxic ROS in response to stimuli47. 
 A recent research suggests that during neuroinflammation, NADPH oxidase plays a 
critical role in modulating the microglial phenotype towards a pro-inflammatory activated state 
48. In the same study, it was demonstrated that inhibition of NADPH oxidase increases 
production of anti-inflammatory cytokines such as IL-4, reducing the production of pro-
inflammatory cytokines such as TNF-α48. Finally, this enzyme is described as an essential 
player for pro-inflammatory events that occur in some disorders such as AD49.  
 Macrophage antigen complex 1 (MAC1) 
  This complex, also known as complement receptor type-3 (CR3) or integrin CD-
11b/CD-18 is bifunctional, acting as an adhesion molecule, and as a pattern recognition 
receptor (PRR) which recognizes a diverse set of stimuli, mediating the activation of 
phagocytes50, 51. 
The MAC1 receptor is highly expressed in post-mortem brains of patients with AD8, 
matching the microglial activation that occurs in this neurodegenerative disorder. Moreover, 
MAC1 has been described as a player in NADPH oxidase activation in response to oxidative 
insults51-53. In addition, when MAC1 receptor receptor recognizes a ligand, an induction of the 
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transcription factor NF-κB signaling pathway and the resulting production of inflammatory 
factors were verified54. 
 A model family of pattern recognition receptors: Toll-like receptors (TLRs) 
TLRs are one of the most studied families of PRRs as they contribute for the 
immunocompetent cell activation in the CNS and the subsequent pro-inflammatory cascade. 
In microglia, the expression of TLRs is regulated by signaling cascades during embryonic 
development and by the exposure to inflammatory triggers, such as pathogens55. 
There are twelve members of the TLR family identified in mammals that recognize 
PAMPs from bacteria, fungi, viruses and the host itself  56. The recognition of PAMPs by these 
receptors initiates innate immune responses on interaction with infectious agents. In microglia, 
which expresses the TLRs from 1 to 957, 58, TLR4 is accepted as the primary LPS receptor59 
and has been reported to be a crucial mediator of the inflammatory response to LPS60, 61. 
Additionally, TLR4 also respond to damage associated molecular patterns, released by the 
injured tissues, and is upregulated upon brain inflammation61, 62, strongly suggesting a role of 
this receptor as pro-inflammatory mediator.  
 Cell surface immune-associated receptors 
Many cell surface receptors associated with the innate immune system response such 
as MHC molecules are also upregulated during microglial activation through an inflammatory 
stimulus (Figure 4). The abundance of those molecules during microglial activation allows 
these cells to act as antigen presenting cells (APC) to T-cells that will then be able to enter the 
brain in the course of an active infection6. As example, CD-40, which is a typical T-Cell surface 
receptor and a member of the tumor necrosis factor receptor (TNFR) family63, is over-
expressed by activated microglia64, 65. Also, CD-45, the leukocyte common antigen, is highly 
expressed in constitutively activated microglia from OX2-deficient mice9. However, CD-45 level 
of expression is lower when compared to macrophages7, 66, and the same occurs with many 
other immune-associated receptors. 
 
Figure 4 – Markers of microglial activation. When exposed to an inflammatory stimulus, membrane immune 
receptors are highly expressed (A) and inflammatory cytokines are secreted, accompanying the shift for the 
amoeboid morphology (B). Adapted from R. N. Dilger, R. W. Johnson, J Leukoc Biol 84, 932 (2008)67. 
Inflammatory 
stimulus 
(e.g. LPS, 
TNF-α, IFN-γ) 
NO 
ROS 
    Surveillant 
  microglia cell 
Activated 
microglia cell 
A B 
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 Expression of cytokines and chemokines 
Important cytokines and chemokines such as IL-1β, TNF-α13, 14 (Figure 4) and also 
monocyte chemoattractant protein-1 (MCP-1) are molecules that constitute good markers of 
microglial activation. Those molecules are characteristic of macrophage and chemoattractant 
cells, whereas its abundance in microglia indicates a shift for the phagocytic phenotype68.  
 Chronic releasing of those cytokines by pro-inflammatory microglia may also have a 
deleterious role, inducing neurodegenerative complications by binding to specific cell surface 
receptors expressed in neurons and further activating apoptotic pathways69. As example, TNF-
α binds to tumor necrosis factor receptor-1 which promotes apoptosis in neurons70. 
Dysregulation of this cytokine is implicated in AD71 and cancer72, as well. 
 Production of ROS and NO 
As previously described, NADPH oxidase activation is directly involved in the synthesis 
of superoxide, which is the main responsible for ROS production in activated microglia. ROS 
have a crucial role by enhancing host defenses against pathogens; acting also as mediators 
of cellular signaling for cytokine synthesis73; and contributing for the cellular homeostasis. On 
the other hand, increased ROS production by chronically pro-inflammatory activated microglia 
can directly damage the surround tissues, contributing for further pro-inflammatory events74, 75. 
For instance, O2• - is a good example of immediate ROS released by microglia in 
response to stimulus76. Even so, microglial LPS-induced production of O2• - is not mediated 
through the traditional LPS receptor TLR4; instead, MAC1 is the responsible for NADPH 
oxidase activation and the subsequent production of O2• -    77. 
Also, another important marker excessively released by overactivated microglia during 
pro-inflammatory events is NO, which have been reported as inducing neuronal death by 
damaging the mitochondrial electron transport chain, and therefore resulting in neuronal ATP 
synthesis disruption, increasing the generation of ROS78, 79.  
 Other markers: Ion channels 
Another important pro-inflammatory marker that has been suggested as playing an 
important role in regulation of microglial activation is ionized calcium binding adapter molecule-
1 (Iba-1)80. It is a calcium-binding protein that is specifically expressed in macrophages and 
microglia81, being upregulated during the activation of these cells. In microglia, Iba-1 
expression is up-regulated in response to nerve injury, which occurs in several 
neurodegenerative disorders82.  
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2.2.2 – Common Inflammatory triggers 
 An extensive list of pro-inflammatory stimuli, including LPS; pesticides such as 
paraquat, dieldrin, lindane or rotenone; known disease proteins like beta-amyloid (Aβ) or 
alpha-synuclein (α-SYN); damaged neurons and even air pollution are capable of inducing pro-
inflammatory microglial activation21. Some authors have proposed that all these stimuli develop 
a toxic microglia response due to its misinterpretation as a pathogen46. 
 LPS is one of the most effective stimuli described to promote an inflammatory response. 
It consists of a cell wall component from gram-negative bacteria and is known by inducing 
activation of many pathways such as protein kinase C, protein-tyrosine kinases, MAPK, and 
NF-κB47. These pathways are implicated in the release of pro-inflammatory cytotoxic factors, 
such as NO and some cytokines83-85. Its systemic administration in wild-type mice activates 
microglia and increases expression of pro-inflammatory factors such as TNF-α, MCP-1, IL-1β, 
and NF-κB86. 
 Another common neuroinflammatory agent is rotenone87. It is a lipophilic compound 
vulgarly used as a natural pesticide (herbicide and insecticide), and it can easily cross the 
BBB88. Due to its high inflammatory efficiency, it is also used to induce Parkinsonism in 
rodents89 and has been reported to increase superoxide (O2• -) production by stimulating the 
microglial phagocyte NADPH oxidase (PHOX)87. 
 
2.3. Attenuation of neuroinflammation by dietary factors  
 As a major aspect of the environment, diet plays a crucial role in the modulation of 
inflammation. Certain dietary components such as polyphenols, found in fruits, vegetables, 
nuts, whole grains; and omega-3 fatty acids found in many sea origin foods, seem to promote 
attenuation of chronic pro-inflammatory processes associated with chronic diseases90.  
 However, since industrial revolution, dietary habits of the Western civilization have 
changed with the development of agriculture and food processing industry. Nowadays diet is 
based on high intakes of red meat, sugary desserts, high-fat foods, refined grains, and 
carbonated beverages, accompanied by a low intake of fresh and dried fruits, nuts, vegetables, 
whole grains, insoluble fiber, fish, and walnuts. These dietary habits contribute for the 
increasing of chronic inflammatory diseases verified in the mentioned civilizations91, 92. The 
following table resumes dietary factors that promote or retard inflammation. 
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Table 1 - Dietary factors that are described as pro- and anti-inflammatory. Adapted from X. Wu, A. G. Schauss, J 
Agric Food Chem 60, 6703 (2012). 
 
Pro-inflammatory dietary factors Anti-inflammatory dietary factors 
 High-fat diet, including hydrogenated 
unsaturated plant fats (“artificial” trans fats) 
 Diets with high glycemic index 
 Diets low in fruits, vegetables, raw nuts, 
and whole grains 
 Sugar-sweetened carbonated and non-
carbonated beverages 
 Insufficient intake of fruits, vegetables, 
nuts, whole grains and omega-3 enriched 
food 
 Hidden or delayed food allergies promoting 
inflammation 
 Diets rich in monounsaturated and omega-
3 fatty acids 
 Diets with a greater variety of fruits, 
vegetables, raw nuts, and whole grains 
 Diets high in soluble and insoluble fibers 
 Diets low in refined grains or minimally 
processed whole grains 
 Diets rich in polyphenols including tea, 
cocoa, red wine, berries and fruits. 
 
2.3.1 – Attenuation of neuroinflammation by polyphenols 
 Among all dietary phitochemicals, polyphenols are considered the major anti-
inflammatory molecules provided by berries, vegetables, tea, coffee, grains and legumes93. 
These important molecules are characterized by one or more aromatic rings with one or more 
hydroxyl groups, and are derived from plant’s secondary metabolism. More than 8000 
polyphenols at the whole plant kingdom have been reported, many of them present in food94. 
The molecular structure of most abundant polyphenols found in the human diet is presented 
in Attachment 1. 
 The way polyphenols act as anti-inflammatory agents is not straightforward, but it is 
accepted that they can regulate enzymes involved in the role of inflammatory events. Some of 
those enzymes are glutathione peroxidase95, nitric oxide synthase (iNOS), cyclooxygenase-2 
(COX-2), and lipooxygenase (LOX), which are involved in the production of many mediators 
of inflammation, such as NO, arachidonic acid or prostaglandins96, 97.  
Recently, the hormesis theory has been associated with some polyphenols as their 
biological mechanism. Some studies revealed that they can actually promote cellular toxicity 
and stress at high concentrations98. However at the physiologic cellular level, polyphenols are 
usually found in very low concentrations which promotes a hormetic response, stimulating 
adaptive cellular stress pathways98. Precondition with polyphenols can stimulate those 
adaptive pathways, becoming more effective in the prevention and attenuation of severe 
neuroinflammatory processes99, 100. As example, LPS-induced NF-κB activation in microglia is 
inhibited by the pre-treatment with polyphenols101.  
Increasing evidences suggest that flavonoids inhibit the production of pro-inflammatory 
cytokines such as TNF-α, IL-6 and IL-1, suggesting its close involvement in pathways such as 
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NF-κB or MAPK102, 103. Catechins, the major polyphenolic components of green tea, are a group 
of flavonoids with several anti-inflammatory properties. According to clinical trials and animal 
studies, chronic tea drinking leads to inhibition of low-level inflammation due to alterations in 
various inflammatory markers104. In addition, there is strong evidence that blueberry 
polyphenols inhibit production of NO, IL-1β and TNF-α in activated microglial cells105.  
Additionally, many studies show that polyphenols delay and slow the progression of 
neurodegenerative disorders, such as AD, by inhibiting neuronal apoptosis promoted by 
release of neurotoxic species and pro-inflammatory mediators106, 107.  
 
2.3.2 – Polyphenols metabolites 
 Despite all the beneficial effects achieved with undigested polyphenols, its utilization is 
limited because, in vivo, those compounds result in metabolites with different biological 
properties due to digestion, absorption and metabolization. 
 For example, whereas quercetin exhibits strong anti-inflammatory activity by 
attenuating NOS production108 and preventing the release of inflammatory cytokines in 
microglia109, 110, one of its largest metabolites, quercetin-3’-sulfate, failed in evidencing such 
anti-inflammatory activity111. 
 Conversely, many polyphenol metabolites have stronger anti-inflammatory effects than 
their precursor molecules. A study comparing 45 different polyphenolic compounds showed 
that both flavanols (+)-catechin and (-)-epicatechin did not inhibit NADPH oxidase unlike their 
most common methylated metabolites, which exhibited strong NADPH oxidase inhibition112.  
Many studies converge at suggesting that polyphenols have positive effects against 
neurodegenerative disorders, thus these particular molecules are crucial to keep under study. 
However, the study of polyphenols metabolites is imperative to get conclusions that can be 
more trustful about its real health benefits. 
 
2.3.3 - Raspberry: a fruit with potential anti-neuroinflammatory properties 
Raspberries are edible berries that represent an important commercial crop, widely 
grown in all temperate regions of the world. These berries belong to genus Rubus, from 
Rosaceae family. An important species is the red raspberry (Rubus idaeus), which is widely 
cultivated in Europe and Asia113; another is the eastern North American black raspberry (Rubus 
occidentalis)114. 
Raspberries and other small fruits are known to represent a great source of natural 
antioxidants115, including polyphenols such as ellagic acid, flavanols; and phenolic acids116. 
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Therefore, these fruits have increased their popularity in the human diet. Certainly, one of the 
most famous antioxidant sub-classes found on these berries are anthocyanins. Although the 
interest in these compounds first aroused due to its antioxidant properties, most recent studies 
suggest that the beneficial health effects are also associated with their chemopreventative and 
anti-inflammatory properties. As example, the beneficial biological activity of black raspberry 
against esophageal, colon, and oral cancers has been demonstrated117. In addition, these fruits 
are also an enriched natural source of other phytochemicals such as flavonols, phenolic acids, 
ellagic acids and β-sitosterol, as well as the vitamins C, E and folate. 
In respect to anti-inflammatory capacity, anthocyanins118 and ellagitannins are 
independently described as biological molecules acting as anti-inflammatory agents. 
Ellagitannins and their colonic derived metabolites have shown anti-inflammatory capacity in 
rats, reducing the levels of prostaglandin E2 (PGE2), NO production, iNOS and many other 
markers119. Similarly, another study concluded that ellagitannins and their colonic metabolites 
also suppressed arthritis incidence and inflammatory markers in the arthritic joints120. 
Red raspberry polyphenolic-enriched extract, typically a complex mixture, mainly 
composed by ellagitannins and anthocyanins but also by ellagic acid glycosides and flavonol 
conjugates121, has demonstrated anti-inflammatory properties in vivo118, 122. 
   
 
 
3. Materials and methods 
3.1. Plant material, in vitro digestion and fractions preparation 
For this research, 5 different digested raspberry polyphenolic fractions were obtained 
and provided by Dr. Derek Stewart, from the Division of Enhancing Crop Productivity and 
Utilisation, at James Hutton Institute, England.  
The raspberries were originally harvested from the different germplasm lines (quasi-
isogenic cultivars) generated by artificial selection in James Hutton Institute (JHI), Invergowrie, 
Dundee, Scotland, in 2012 (Table 2). The harvest of each quasi-isogenic raspberry was mixed, 
then freeze-dried. A chemical characterization of the polyphenolic content present in the fruits 
was also performed and presented in Attachment 2. The freeze-dried powder was rehidratated 
by shaking water (2 g in 20 mL) prior to submission to an in vitro digestion model, previously 
described by McDougall et al, 2005 123.This model mimics gastric digestion under pH 1.7 by in 
the presence of pepsin incubated with shaking at 0.56 x g at 37ºC for 2h; and small intestine 
digestion by the interaction with pancreatin and bile salts. At the end of the digestion process, 
the resulting digested fractions were dialyzed for 2h at 37ºC with a cellulose tube containing 
NaHCO3 to neutralize titratable acidity. The solution that entered the dialysis tubing (fraction 
“IN”) and the solution outside the dialysis tubing (fraction “OUT”) were both collected, 
representing respectively, the bio-accessible fractions to serum and to colon. Both fractions 
were applied to a C18 solid phase extraction (SPE) column (GIGA tubes, 1000 mg capacity, 
Phenomenex Ltd.) for the removal of possible interfering compounds from the in vitro digestion 
model124. In the present work, only the “IN” fractions were used (Table 2).  
Table 2 – Different raspberry crops obtained from each of the five quasi-isogenic cultivars. The berries from each 
cultivar were submitted in vitro digestion. The final digested fractions (specifically, the bio-accessible fractions to 
serum – fractions “IN”) were used at the present work. The correspondent designations attributed during this work 
are presented bellow each fruit. 
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3.2. Microglial model of neuroinflammation  
3.2.1 – Cell culture and treatments 
The N9 murine microglial cell line was a gift from Dr. Teresa Faria Pais (Institute of 
Molecular Medicine, Lisbon). Cells were cultured in EMEM (Eagle Minimum Essential Media) 
supplemented with 10% fetal bovine serum (FBS) (Gibco®), L-glutamin (200 mM), 1% (v/v) 
non-essential amino acids (NEAA) (Sigma–Aldrich® - Poole, Dorset, UK) and maintained at 
37ºC in an humidified atmosphere of 5% (v/v) CO2. No antibiotics were used. Cells were 
detached by agitation before suspension of the culture media with pipette. (No detaching 
agent, like trypsin, was used). Cell confluence was also monitored, avoiding cells to reach 
confluences higher than 80%.  
For the neuroinflammatory model establishment, N9 murine microglial cells were plated 
onto 6-well plates (5 x 105 cells . mL-1) and cultured overnight to reach a confluence of 50-
60%. Then, cells were stimulated with LPS (Sigma–Aldrich® - Poole, Dorset, UK)  [100 to 500 
ng . mL-1] during 24 hours, in order to release pro-inflammatory mediators, such as NO18 and 
TNF-α15 in the media (see 3.2.3 section). CD-4064 and superoxide76, whose 
expression/production is increased upon microglia activation, were quantified by flow 
cytometry (see 3.2.3 section). Also, Iba-180 was assayed by western blot (see 3.2.3 section). 
To test the capacity of the different fractions (see chapter 3.1) in attenuation of 
neuroinflammation, N9 microglial cells were plated onto 6-well plates (5 x 105 cells . mL-1) and 
cultured overnight to reach a confluence of 40-60%. Then, cells were pre-incubated with the 
digested raspberry polyphenolic fractions [1 to 1.25 µg GAE . mL-1] during 2 to 24h. At this 
stage, FBS concentration was reduced to from 10% to 0.5% (v/v), avoiding protein-polyphenol 
interactions and further precipitation. It was assured that the reduction of the FBS 
concentration did not affected the viability and functionality of the cells. After incubation with 
the fractions, media was discarded and cells were washed once with phosphate buffer saline 
(PBS) 500 µL prior to addition of fresh media with 10% FBS with LPS [100 to 500 ng . mL-1]. 
The inflammatory mediators validated in the model establishment (NO, TNF-α, CD-40 and 
superoxide) were assessed by using same methodologies. 
3.2.2 – Protein extraction and quantification 
Protein extraction and quantification was assayed for the normalization of the results 
and for western blotting. Cell media was removed and 150 µL of RIPA buffer [50 mM Tris 
(CarlRoth® – Schoemperlenstr, Karlsruhe, Germany); 150 mM NaCl (Sigma–Aldrich® - Poole, 
Dorset, UK); 0.1% (w/v) Sodium dodecyl sulfate (SDS) (Merck® - Frankfurter Straße, 
Darmstadt, Germany); 0.05% (w/v) sodium deoxycholate (Sigma–Aldrich® - Poole, Dorset, 
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UK); 1% (v/v) NP-40; 0.05% (v/v) cocktail protease inhibitors (AppliChem Inc - Mary Avenue, 
Missouri, USA) ; and 0.4% (v/v) DNAse (Roche® – Basel, Switzerland)] were added. After 
incubation for 15 minutes at room temperature, the lysate was scrapped, transferred into 
microtubes and centrifuged (10 minutes; 4ºC; 8000 x g). The lysate was stored at -80ºC and 
protein determination was performed by Lowry protein assay125. 
3.2.3 – Determination of pro-inflammatory and activation markers 
 Nitric Oxide measurement by Griess Reaction 
Because of the relatively short half-life of NO in aqueous solution, its quantitative 
measurement usually is indirectly accessed by the quantification of its oxidized products, nitrite 
and nitrate, which are regarded as suitable markers of NO release. The choice of the detection 
method depends on the type of cell and on the released quantity126, 127.  
For this experiment, it was used the Griess Reagent (Sigma–Aldrich® - Poole, Dorset, 
UK), which measures nitrite (Figure 5). For analysis, 100 µL of cell culture medium were quickly 
removed from each well of the culture plate and added to a 96-well plate for reading. For nitrite 
quantification, a standard curve of sodium nitrite [0 to 25 µM] was prepared. Equal volumes of 
Griess reagent were added to each well. The plate was incubated for 15 minutes at room 
temperature and the absorbance (Abs) was read at 540 nm.  
 
Figure 5 - Griess reaction scheme. This reaction allows the detection of organic nitrite compounds and was first 
described in 1858 by Peter Griess. This image belongs to the public domain, and contains no original authorship. 
 
 TNF-α quantification by ELISA 
Cell supernatants were harvested after 24h and stored at -80ºC until analysis. TNF-α 
release was assayed by sandwich ELISA (Enzyme-Linked Immunosorbent Assay) according 
to the manufacturer’s instructions (PeproTech®; Princeton Business Park, Rocky Hill NJ, 
United States)128. All the reagents and plates used were provided in the kit. For the standard, 
recombinant murine TNF-α was diluted from 2 ng . mL-1 to zero in diluent. Antigen-affinity 
purified goat anti-murineTNF-α diluted 1 µg . mL-1 in PBS was used as capture antibody. As 
detection antibody, it was used a biotinylated antigen-affinity purified goat anti-murineTNF-α 
diluted 0.25 µg . mL-1 in diluent. As substrate, Avidin-HRP conjugate diluted 1:2000 (v/v) in 
diluent was used. 
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Finally, as liquid substrate, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 
(ABTS) was used in the stock concentration. The plate was incubated at room temperature in 
a Synergy HT microplate reader, from Biotek® for 35 minutes, with 5-minute intervals Abs405 
readings.  
 CD-40 and superoxide (O2•-) quantification by flow cytometry 
Culture media was discarded and 1 mL PBS was added to detach N9 adherent cells, 
which were then incubated with 1 mL mouse anti-FcγR (same as CD-16/32, from E-
Biosciences) in FACS buffer (PBS containing 2% fetal calf serum and 0.01% NaN3) for 30 
minutes at 4ºC before staining. Anti-FcγR was required for the blocking of Fc-mediated 
reactions with other specific antibodies129. Cells were spun down at 1000 x g, washed once 
with 500 µL FACS buffer and doubly stained with 5 µg . mL-1 mouse anti-CD40 conjugated 
with fluorochrome FITC (clone 3/23, from BD Biosciences®); and with 5 µg . mL-1 DHE probe 
(Dihydroethidium, Invitrogen™, Carlsbad, CA, USA) as superoxide indicator. Events were 
acquired using CUBE 6 cytometer, from Partec®. Post-acquisition analysis was done with the 
software FSC express 4 flow research edition®. 
 Iba-1 determination by Western Blot  
For Western Blot analysis, 40 μg of total protein lysate from each treatment were 
separated by SDS-PAGE on a 12% (w/v) acrylamide gel. After electrophoresis, proteins were 
transferred to a polyvinylidene difluoride membrane, during 90 minutes at 70 Volt (V), 4ºC.  
The membrane was blocked in a solution of 5% (w/v) of membrane blocking agent (MBA) (GE 
Healthcare™, Wilmington, MA, USA) diluted in TBST (50 mM Tris; 150 mM NaCl; 0.05% 
Tween 20), and incubated for 1h with agitation at room temperature. Then, the membrane was 
incubated primary antibody [rabbit anti-iba1 (0.7 µg . mL-1) from WAKO] overnight, at 4ºC. After 
washing 3x with TBST for 5 minutes, secondary antibody was added [goat anti-rabbit IgG HRP-
conjugated (1:300), from Millipore] and the membrane incubated for 2h, with agitation at room 
temperature. Membrane was washed 3x during 5 minutes with TBST and additionally washed 
1 minute with TBS (50 mM Tris; 150 mM NaCl) prior to enhanced chemiluminescence 
substrate (ECL) addition (PhemtoMax Super Sensitive Chemiluminescence HRP Substrate, 
Rockland, Gilbertsville, USA). Proteins were visualized by chemiluminescent detection using 
Molecular Imager ChemiDoc XRS (Quantity One™ software v.4.6.6; BioRad®, Amadora, 
Portugal).  
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3.2.4 – Cytotoxicity assays 
Cytotoxicity of raspberry digested polyphenolic fractions was tested with cell viability 
assay (CellTiter-Blue Cell Viability Assay, Promega®). This assay uses the indicator dye 
resazurin to measure the metabolic capacity of cells as an indicator of cell viability. Viable cells 
retain the ability to reduce resazurin into resorufin, which is highly fluorescent. Nonviable cells 
rapidly lose metabolic capacity, do not reduce the indicator dye, and thus do not generate a 
fluorescent signal130. 
Cells were plated into 96-well plates (5 x 105 cells . mL-1 for final volumes of 100 µL per 
well). After 24 hours of growth, four concentrations (0.25; 0.5; 1 and 2 µg GAE . mL-1) of the 
five digested raspberry fractions were applied. The fractions were dissolved in culture media 
with 0.5% FBS to avoid major protein-polyphenol interactions and further precipitation. After 
21h of incubation with fractions, 20µL of CellTiter-Blue reagent was added to each well. The 
plate was briefly shaken and incubated again with standard cell culture conditions for 3 hours 
(performing 24h of total incubation time with fractions). Fluorescence values were recorded in 
a Synergy HT microplate reader, from Biotek® and normalized for viability percentage relatively 
to control. 
3.3. Yeast model of inflammation  
3.3.1. Characterization of Saccharomyces cerevisiae model of inflammation 
As previously described in the Theoretical Fundaments section, NFAT modulates 
microglial activation. This transcription factor has an orthologous gene in yeast – CRZ1. Crz1 
is also regulated by calcineurin, a calcium dependent enzyme, in a very similar manner as 
NFAT does in mammalian cells131. When dephosphorylated by calcineurin, Crz1 translocates 
from the cytosol to the nucleus and binds to the calcineurin-dependent response element 
(CDRE)132, 133. While in mammals NFAT binds to diverse promoters that activate pro-
inflammatory gene expression40, 41, in yeast, Crz1 binding to CDRE promotes activation of 
genes related to the response against cellular stress, such as ion pumps134, 135. These 
regulatory similarities are the basis for the use of this microorganism as an eukaryote model 
of inflammation. 
YAA5, a S. cerevisiae transgenic strain obtained from the wild-type BY4742, makes 
use of β-galactosidase expression as a reporter system to infer the anti-inflammatory potential 
of compounds. Additionally, the strains YAA6 and YAA7 are both used as negative controls. 
While YAA6 carry a deletion of CRZ1, YAA7 is devoid of CNB1, which encodes the regulatory 
subunit of calcineurin. The genotypes of each strain are presented in the Table 3 136. 
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Table 3 - S. cerevisiae strains used in this work. (From, R. T. Ferreira et al., Microbiology 158, 2293 (2012)). 
Strain Genotype Source or 
reference 
BY4742 MATa his3 leu2 lys2 ura3 EUROSCARF* 
YAA5 MATa his3 leu2 lys2 ura3 aur1 : : AUR1-C-4xCDRE-lacZ Araki et al. (2009) 
YAA6 MATa his3 leu2 lys2 ura3 YNL027W : : HIS3MX4 aur1 : : AUR1-C-4xCDRE-lacZ Araki et al. (2009) 
YAA7 MATa his3 leu2 lys2 ura3 YKL190W : : kanMX4 aur1 : : AUR1-C-4xCDRE-lacZ Araki et al. (2009) 
* EUROpean Saccharomyces Cerevisiae ARchive for Functional analysis.  
  
Calcium is the most common used inducer of Ca2+-signaling pathways137, since it is 
captured and accumulated by calmodulin, which can effectively stimulate calcineurin 
phosphatase activity138. However, other molecules/ions are described as indirect inducers of 
the system139, such as Mn2+ or Li+.   
3.3.2 – β-galactosidase assays 
Quantification of β-galactosidase activity was performed using different colorimetric 
substrates. Qualitative measurements were carried out in agar plates where yeast colonies 
were overlaid with an agarose solution containing 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal) (ImmunoSource® - Ruiterslaan 29, Zoersel, Belgium). Quantitative 
measurements were performed in a 96-well plate with cell lysates exposed to the colorimetric 
substrate Ortho-Nitrophenyl-β-galactoside (ONPG) (Sigma–Aldrich® - Poole, Dorset, UK). 
 Qualitative assay 
Yeast strains were grown overnight at 30ºC with agitation in synthetic complete media 
(SCM) (Table 4) to the exponential growth phase. In the following day, the Abs600 was 
measured and 4 x 107 cells were centrifuged at 900 x g for 3 minutes and resuspended in 1 
mL SCM. The anti-inflammatory potential of fractions was tested by incubating cells with 100 
µg GAE . mL-1 of the five digested raspberry polyphenolic fractions (R1, R2, R3, R4 and R5). 
Immunosuppressant macrolide drug FK506 (Sigma–Aldrich® - Poole, Dorset, UK) dissolved in 
dimethylsulfoxide (DMSO) was used as positive control (6 µg . mL-1). Cells were incubated for 
90 minutes at 30ºC with agitation. After incubation, cells were centrifuged at 900 x g for 3 
minutes and the supernatant was discarded. Cells were washed with three time with PBS to 
remove polyphenols. The supernatant was completely removed and the cells were 
resuspended in 5 uL of SCM. Cells were spotted onto agar-SCM supplemented or not with 1.8 
mM MnCl2. Cells were incubated for 90 minutes at 30ºC before X-Gal overlay - Agarose 
solution was applied [0.2% (w/v) SDS; 2 mg . mL-1 X-Gal (solubilized in dimethilformamide); 
0.5% (w/v) agarose; 50% (v/v) Lac Z buffer (8.5 g . L-1 Na2HPO4; 5.5 g . L-1 NaH2PO4 ● H2O; 
0.75 g . L-1 KCl; 0.246 g . L-1 MgSO4 ● 7H2O)]. After few minutes, cells exhibiting β-galactosidase 
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activity start to develop the indigo color, which is proportional to the activation of Crz1. Images 
were recorded each 10 minutes for 2h (Menezes et al; 2003; with modifications). 
Table 4 - Synthetic complete media constitution. 
Constituent Final concentration 
Complete supplement mixture 
(CSM) (QBiogene®) 
0.79 g . L-1 
Yeast nitrogen base (YNB)  
(Difco®, USA) 
0.67% (w/v) 
Glucose (Sigma–Aldrich® - Poole, 
Dorset, UK) 
2% (w/v) 
 Quantitative assay 
Yeast strains were pre-cultured in SCM overnight at 30ºC with agitation to obtain cells 
in exponential growth phase. In the following day, cells were diluted in fresh SCM and cultured 
for 8h at 30ºC. Then, Abs600 was measured and cells were again diluted to obtain cultures with 
Abs600 1 after an overnight incubation. Once reached Abs600 1, cells were diluted in fresh SCM 
to a final Abs600 0.1 and 300 L of cultures were transferred into microtubes. As a pre-
treatment, 100 µg . mL-1 of the five digested raspberry polyphenolic fractions (R1, R2, R3, R4 
and R5) were applied. As positive control, 6 µg . mL-1 of FK506 dissolved in DMSO were used. 
Final volumes of each pre-treatment were equalized in order to avoid interference in the Abs600. 
Pre-treated cells were incubated for 90 minutes at 30 ºC. After incubation, cells were 
thoroughly resuspended and 150 µL were transferred to a second microtube containing 1.8 
mM MnCl2. Induced and control cells were incubated for 90 minutes at 30ºC. After incubation, 
microtubes were thoroughly resuspended and 10 µL of the cell suspension from each 
treatment were transferred onto a 96-well plate containing 20 µL Y-PER cell lysis reagent 
(Pierce® Protein Research, USA) per well. Three technical replicates were generated from 
each microtube. The plate was incubated for 20 minute at 30ºC for cell lysis. For the β-
galactosidase activity quantification, 240 µL of a solution containing 1 mg . mL-1 ONPG 
dissolved in Lac-Z buffer (8.5 g . L-1 Na2HPO4; 5.5 g . L-1 NaH2PO4 ● H2O; 0.75 g . L-1 KCl; 0.246 
g . L-1 MgSO4 ● 7H2O) were added to each well. The plate was incubated in a Synergy HT 
microplate reader, from Biotek® for 2h at 30ºC and absorbance readings at 420 nm were 
performed every 10 minutes. 
3.4. Statistics 
 Data are presented as mean values ± standard errors (SE) or standard deviations (SD). 
Statistical differences were tested using unpaired one-way ANOVA with Tukey post hoc 
comparison, and considered significant when p<0.05.   
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4. Results and Discussion 
 
4.1. Attenuation of neuroinflammation in murine microglial cell line N9 
4.1.1 – Implementation of N9 microglial line as a neuroinflammation model 
In order to implement a neuroinflammation model with N9 murine microglial cell line, a 
set of markers that can easily distinguish activated cells from non-activated cells were 
monitored after LPS stimulation. Therefore, a battery of compounds that have been described 
as mediators of microglial activation, such as NO79, TNF-α14, CD-4064, 140, (O2•-)76 and iba-182 
were evaluated.  
N9 microglial cells were stimulated with 100, 300 and 500 ng . mL-1 LPS for 24 hours 
and culture media was evaluated for NO and TNF-α levels, by Griess reaction and quantitative 
ELISA, respectively. Adherent cells were lysated for protein quantification to further normalize 
the results.  
As presented in figure Figure 6, the higher the dose of LPS, the higher is the secretion 
of NO and TNF-α. Secretion of NO shows a linear dose-response relatively to the tested LPS 
concentrations (y = 0.04x + 14.06 ; R² = 0.83), despite not having detected significant 
difference on the level of NO between treatments. TNF-α quantification seems to describe a 
different tendency, in which there are significant differences between 100 and 300 ng . mL-1 
LPS, but no significant difference between 300 and 500 ng . mL-1. 
 
Figure 6 - Quantification of secreted nitrite measured by Griess reaction (A); and secreted TNF-α measured by 
quantitative ELISA (B). Control cells (solid fill bars) and cells stimulated with 100, 300 and 500 ng . mL-1 of LPS for 
24h (striped bars). Statistics are representative of three biological replicates. Data were normalized for the extracted 
protein in each treatment with ± SE. * represents statistical significant differences between each treatment and the 
control. + represents statistical significant differences between indicated treatments. [*** and +++ p < 0.001; ** p < 
0.01; n.s. p ≥ 0.05 (not statistically significant)]. 
To access CD-40 and O2•-, N9 cells were stimulated with LPS and stained with specific 
probes for each marker. Flow cytometry assay was performed as described in the methods. 
The results show a significant increase in both CD-40 expression and O2•- production, with the 
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increasing LPS dose (Figure 7). Both markers, CD-40 and superoxide increase with LPS 
stimulation and cell response is clearly detected even for the lower LPS dose. 
 
 
 
 
 
 
 
 
 
 
 
These results clearly demonstrate that even the lowest LPS concentration tested 
significantly increased NO, TNF-α, CD-40 and O2•- levels, accordingly with the literature13, 64, 
141, 142. However, from the three LPS concentrations tested, 300 ng . mL-1 LPS was selected 
for further experiments. Among all the tested inflammatory markers, this concentration always 
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Figure 7 – Expression of CD-40 and production of intracellular O2.- quantified by flow cytometry analysis of N9 
microglial cells stimulated with different LPS concentrations [0 (control), 100, 300 and 500 ng . mL-1 LPS] for 24h. 
A - Histograms of the fluorescence intensity counts (FIC) for CD-40 and O2.- in N9 cells after treatment with different 
LPS concentrations. Each of the first three histograms (for both CD-40 and O2.-) represent the FIC overlays of the 
cells stimulated with the respective above indicated LPS concentration (black line) and the control cells (solid fill 
gray). The red lines on CD-40 histograms indicate the threshold between cells with high and low signal. This 
threshold was defined relatively to the control, assuming cells as expressing low levels of CD-40 (basal 
expression). The fourth column for each marker present a 3D overlay stack of the 3 histograms visualized for each 
LPS concentration, plus the control. B - Percentage (%) of gated cells that highly expressed CD-40. C - Median 
fluorescence intensity (MFI) relative to O2.- production. Control cells (solid fill bars) and cells stimulated with 100, 
300 and 500 ng . mL-1 LPS (striped bars). Statistics are representative of three biological replicates for each 
treatment. Data is presented as mean ± SE. * represents statistical significant differences between each treatment 
and the control. *** p < 0.001. 
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revealed a large difference between control and activated cells and was not statistically 
different from 500 ng . mL-1, which is important for the evaluation if it occurs an inflammatory 
attenuation by polyphenolic digested fractions.  
 Additionally, flow cytometry analysis allowed the confirmation of consistent 
morphological alterations in cells observed at microscope and previously described in the 
literature as occurring during microglial activation4, 10. By analyzing forward scatter versus side 
scatter, two physical markers for size and complexity respectively, there is notably a new sub-
population that is believed to be activated amoeboid microglia (Figure 8 - B). This microglial 
sub-population is highly increased in LPS-stimulated microglia, even so it consists of a minority 
(32.27%) in total analyzed microglia. 
Figure 8 – (A) N9 control cells. At left, a microscopy image evidencing cell branches and spaced cellular bodies, 
typical in non-activated microglia; at right, a flow cytometry density plot demonstrating the unstimulated microglia 
population with SSC (side scatter) vs FSC (forward scatter). (B) N9 cells stimulated with 300 ng . mL-1 of LPS. At 
left, a microscopy image showing activated cells with a modified morphology, retracted processes and segregated 
vesicles. At right, a flow cytometry density plot evidencing a new sub-population of activated cells. 
 
 
4.1.2 – Cytotoxicity of the digested raspberry polyphenolic fractions 
The cytotoxicity assay did not show significant differences among the five digested 
raspberry fractions, independently of the concentration tested (Figure 9). This means that each 
fraction at any of the concentrations tested, has no significant cytotoxic effects. However, for 
the following experiments, only one concentration (1 µg GAE . mL-1) was chosen to test the 
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Polyphenolic 
content  
(µg GAE.mL-1) 
anti-inflammatory capacity, since it is closer to the described physiological levels of 
polyphenols in blood143. 
 
 
Figure 9 - Cytotoxicity of the digested raspberry fractions in N9 microglial cells. Results were obtained with CellTiter-
Blue cell viability assay and are representative of three biological replicates with ± SE. No significant differences 
were found. 
 
4.1.3 – Model optimization for attenuation of neuroinflammation 
To implement a model that could be used to study the effect of the different digested 
raspberry fractions on the attenuation of neuroinflammation, an assay to identify the best 
incubation time was performed. Due to the limited amount of the digested raspberry fractions 
under study, a different but similar digested raspberry fraction was used in this assay (“HT” - 
Himbo Top digested raspberry polyphenolic fraction), previously tested at host laboratory with 
some evidence in attenuating neuroinflammation (unpublished data). 
For this assay, different times of pre-incubation with HT (1.25 µg GAE . mL-1) were 
tested in LPS-stimulated cells (300 ng . mL-1; 24h), accordingly to literature105, 144. The release 
of NO and TNF-α, was evaluated, as seen in Table 5. Clearly, when comparing the percentage 
of inflammatory attenuation in both inflammatory markers for each different incubation time, it 
was decided to further utilize incubations with 6 hours, since it is the timeframe where the major 
attenuation was detected. 
Table 5 – Percentage of inflammatory attenuation, quantified by released NO and TNF-α, both 
obtained from cells incubated with HT fraction (1.25 µg GAE . mL-1) during 2h; 4h; 6h and 24h. 
Percentages of attenuation and the respective standard errors were obtained by normalization 
for the respective inflammatory positive controls. Significance data is respective to the 
difference between inflammatory positive controls and the cells pre-treated with HT. [*** p < 
0.001; ** p < 0.01; * p < 0.05; n.s. p>0.05 (not statistically significant)]. 
 % of reduction in NO % of reduction in TNF-α 
2h 30.16% ± 5.35%  * 27.66% ± 1.55%  *** 
4h 31.74% ± 2.92%  ** 34.09% ± 4.08% * 
6h 33.18% ± 2.35%  ** 42.52% ± 4.67% *** 
24h 17.73% ± 1.42% n.s. 7.44% ± 1.03% n.s. 
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4.1.4 – Attenuation of neuroinflammation by raspberry digested fractions  
 After the model optimization, the potential to attenuate the neuroinflammation by the 
five digested quasi-isogenic raspberry polyphenolic fractions (R1, R2, R3, R4 and R5) was 
assayed.  The microglial pro-inflammatory markers NO, TNF-α, CD-40 and O2•- were quantified 
after pre-treatment with the digested fractions, followed by LPS stimulation.  
In respect to NO measurement, pre-treatments with all the digested fractions 
significantly decreased the secretion of this pro-inflammatory mediator by N9 microglial cells, 
relatively to inflammatory positive control (Figure 10 – A). Regarding TNF-α quantification, only 
the digested fractions R1, R2 and R5 had significantly reduced the secretion of this cytokine 
(Figure 10 – B). R5 was the digested fraction that most reduced the release of both markers, 
NO and TNF-α.  
 
 
 
 
 
 
 
 
Relatively to the quantification of CD-40 expressed by N9 cells, a significant attenuation 
in the percentage of cells highly expressing this marker was verified when pre-treated with any 
of the tested raspberry digested fractions (R1, R2, R3, R4 and R5) (Figure 11 - A). Even so, 
R3 and R4 exhibited a lower reduction in the percentage of cells highly expressing CD-40, 
compared to R1, R2 and R5 digested fractions. Additionally, R5 was the digested fraction that 
most attenuated the percentage of N9 cells highly expressing CD-40, by reaching 34.73%, 
which is near the non-stimulated cells (20.95%).  
Quantification of superoxide in N9 cells also revealed a significant reduction in the 
production of this marker by cells pre-treated with some of the digested fractions, comparing 
to the positive control (Figure 11 - B). Only pre-treatments with R3 and R4 fractions had no 
significant attenuation in superoxide production. However, from the significant attenuations 
Pre-treatment 
1 µg GAE.mL-1 
   ̶              ̶             R1        R2         R3        R4         R5                Pre-treatment 
                                                                                                            1 µg GAE.mL-1 
    ̶               ̶              R1        R2         R3        R4         R5    
       LPS 
 (300 ng.mL-1) 
                    ̶                                                                          +         +           +          +          +          +                       LPS 
                                                                                                               (300 ng.mL-1)              
                    ̶                                                                         +        +           +         +          +          + 
Figure 10 – Cells were pre-treated with 1 µg GAE . mL-1 of the five raspberry fractions for 6 hours before 
inflammatory stimulation with LPS for 24h. (A) Quantification of the released NO by N9 microglial cells, using Griess 
reaction; (B) quantification of released TNF-α by N9 microglial cells, using quantitative ELISA. Both results were 
normalized for the extracted protein in each treatment with ± SE. Solid white bars represent the cells with no pre-
treatment and no LPS stimulation (inflammatory negative control); Solid grey bars represent cells with no pre-
treatment but with LPS stimulation (inflammatory positive control); Striped bars represent the cells pre-treated with 
the different fractions before LPS stimulation. Statistical data is respective to the differences between each pre-
treatment (striped bars) and the control (solid fill bars). [*** p < 0.001; ** p < 0.01; * p < 0.05; n.s. p ≥ 0.05 (not 
statistically significant)]. 
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promoted by R1, R2 and R5 fractions, the R5 was the most accentuated by nearing the control 
levels. 
 
 
Pre-treatment 
(1 µg GAE.mL-1) 
   ̶                ̶           R1         R2        R3         R4        R5               Pre-treatment 
                                                                                                      (1 µg GAE.mL-1) 
     ̶              ̶             R1         R2         R3        R4        R5 
LPS 
(300 ng.mL-1) 
             ̶             +        +           +         +         +        +                  LPS 
                                                                                                        (300 ng.mL-1)              
   ̶           +         +          +           +         +        + 
Together, these results clearly demonstrate that the five digested raspberry 
polyphenolic fractions act differently as inflammatory attenuators in LPS-stimulated N9 cells. 
The pre-treatments with R3 and R4 fractions clearly evidence a lower capacity in attenuating 
neuroinflammation, since for the TNF-α and O2•- measurements, no significant decrease in 
both pro-inflammatory markers was found relatively to the inflammatory positive controls 
(Figure 10 - B and Figure 11 - B), respectively. In addition, the percentage of cells highly 
expressing CD-40 was not as reduced with R3 and R4, as it was with R1, R2 and R5 pre-
treatments (Figure 11 - A). 
 Oppositely, R1, R2 and R5 pre-treatments significantly reduced the secretion of NO 
and TNF-α, as well as the production of O2•-, and the expression of CD-40, in LPS-stimulated 
cells. Nevertheless, the R5 fraction stands out, considering that, on average it has decreased 
every microglial inflammatory marker more than all the other digested fractions did, suggesting 
its strong contribution for the attenuation of neuroinflammation in general. 
 
 
 
 
 
 
Figure 11 – Expression of CD-40 and production of intracellular O2.- both quantified by flow cytometry analysis of 
stained N9 microglial cells pre-incubated with 1 µg GAE . mL-1 of each digested fraction before pro-inflammatory 
stimulation with 300 ng . mL-1 LPS for 24h. (A) Quantification of the percentage of gated cells that highly express 
CD-40. (B) Quantification of intracellular O2.- production by median fluorescence intensity (MFI). Solid white bars 
represent the cells with no pre-treatment with fraction and no LPS stimulation (inflammatory negative control); Solid 
grey bars represent cells with no pre-treatment but with LPS stimulation (inflammatory positive control); Striped 
bars represent the cells pre-treated with the different fractions before LPS stimulation. Statistics are representative 
of 3 biological replicates with ± SD. * represent statistical significance relative to inflammatory positive controls 
(solid gray bars). [*** p < 0.001; ** p < 0.01; * p < 0.05; n.s. p ≥ 0.05 (not statistically significant)]. 
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4.2. Mechanistic studies of anti-inflammatory properties of digested raspberry 
polyphenols in Saccharomyces cerevisiae models 
 Yeasts are still the most worthwhile organism for studying the relationship between 
genotype and phenotype in eukaryotic cells145. Expression of heterologous proteins in yeast 
cells can facilitate the connection between structure and function in other organisms. This 
strongly validates the use of yeasts as models for primary deduction of functional and 
mechanistic aspects of protein systems shared by eukaryotes146. 
4.2.1 – Digested raspberry polyphenols modulate the Crz1/calcineurin pathway 
 A S. cerevisiae model of inflammation was used to give insights on the molecular 
mechanisms behind the attenuation of inflammation observed for the different digested 
raspberry polyphenol fractions. The model recapitulates the induction of Ca2+-signaling 
cascades leading to the activation of pro-inflammatory genes. Crz1, the yeast orthologue of 
the mammalian NFAT, mediates this activation in S. cerevisiae. For the evaluation of anti-
inflammatory activity of digested raspberry polyphenol fractions, two different assays, both 
using the variations in β-galactosidase activity as reporter to infer Crz1 activation, were used. 
The Crz1/calcineurin pathway was induced with MnCl2139 . 
In the qualitative assay, using X-Gal (see chapter 3.3.2), all the fractions reduced the 
β-galactosidase activity relatively to the control (Table 6). As in the microglia, the digested 
fractions R2 and R5 presented the strongest effect, apparently higher than the FK506 
immunosuppressant. In contrast, R1 and R3 were the digested fractions with the lower 
inhibitory capacity. YAA6 and YAA7 strains, the negative controls, where the Ca2+-signaling 
cascades are disrupted by the deletion of CRZ1 and CNB1 respectively, did not exhibit 
detectable β-galactosidase activity, as expected. 
 
Table 6 – Monitoring of β-galactosidase activity in solid medium using XGgal as a chromogenic substrate. S. 
cerevisiae cells were spotted onto agar plates supplemented with 1.8mM MnCl2 and overlaid with Top-agar 
containing X-Gal. The development of blue color was recorded 50 minutes after overlay casting. On the top line are 
represented the strains and respective treatments used. 
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Attempting to achieve accurate quantitative results, β-galactosidase activity was 
measured in liquid yeast cultures using ONPG (see chapter 3.3.2). This assay demonstrated 
that pre-treatment with all the fractions remarkably inhibited the activity of β-galactosidase 
relatively to YAA5 control cells induced with 1.8 mM MnCl2 (Figure 12 – black bars). R3 
digested fraction exhibited, by far, the lowest capacity to attenuate β-galactosidase activity, 
consistent with the previous results. 
 Regarding the analysis of uninduced cells (Figure 12 – white bars), it is clear a basal 
β-galactosidase activity, which was also significantly decreased after pre-treatment with the 
majority of the digested fractions. Indeed, only R3 yielded no significant differences respective 
to the control. This implies that the majority of fractions not only reduced the β-galactosidase 
expression induced by Mn2+, but also decreased the basal activation of Crz1. 
 
▲ - For the immunosuppressant FK506, the concentration used was 6 µg . mL-1. For all raspberry digested fractions the 
concentrations used were 100 µg GAE . mL-1. 
 
 
 
 
 
 
 
 
Strain    YAA5        YAA5        YAA5         YAA5        YAA5         YAA5        YAA5        YAA6         YAA7 
Pre-treatment ▲        ̶            FK506          R1              R2              R3             R4             R5               ̶                ̶            
Figure 12 – Quantitative β-Galactosidase activity levels, quantified by the hydrolysis of ONPG spectrophotometric 
substrate. Yeast cells were incubated with different pre-treatments, accordingly with the figure. After pre-treatment, 
each sample was equally separated into 2 samples. MnCl2 (1.8 mM) was added as inflammatory inducer to the first 
sample (solid black bars); no inflammatory inducer was added to the second sample (white solid bars). Data 
were obtained from 3 technical replicates and were obtained by reading absorbance at 420nm before normalization 
for the Abs600. Values are presented in mean ± SD. Statistics are relative to the respective control bars (YAA5 with 
no pre-treatment). * and + represent statistical significance relative to cells induced by Mn and not induced cells, 
respectively [*** and +++ p < 0.001; n.s. p ≥ 0.05 (not statistically significant)]. 
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5. Conclusions and future perspectives 
 
This study provided evidence that some digested raspberry polyphenol fractions 
obtained from the five different quasi-isogenic raspberry cultivars strongly attenuate the 
expression/production of diverse neuroinflammatory markers in LPS-stimulated microglia. This 
effect was consistently verified in murine microglial N9 cells, for the pro-inflammatory markers 
CD-40, NO, O2•- and TNF-α after treatments with R1, R2, and especially R5 fractions (Table 
7). However, R3 and R4 fractions demonstrated lower capacity in attenuating some of the 
tested pro-inflammatory markers. 
Table 7 – Final qualitative comparison between the five digested raspberry fractions (R1, R2, R3, R4, R5), regarding 
the results obtained for each different marker in murine microglial N9 cells and the results achieved with the yeast 
model of inflammation. Symbols represent the capacity of each fraction in the attenuation of the respective 
inflammatory marker/technique +++ high capacity; ++ good capacity; + some capacity; 0 no capacity. 
 
 
Also, the reduction evidenced in one specific pro-inflammatory marker by one of the 
digested fractions do not means that the remaining markers follow exactly the same tendency. 
As example, all fractions greatly reduced NO release by LPS-stimulated microglia, even so, 
only R1, R2 and R5 significantly reduced TNF-α release and superoxide production. These 
variations are expected because each quasi-isogenic raspberry has a complex and different 
polyphenolic constitution (Attachment 2), which can differentially interact with the several 
pathways involved in the expression/production of each pro-inflammatory marker. This also 
justifies the use of several markers to assess the anti-inflammatory capacity of compounds.  
Although not critical, ongoing work is being developed with Iba-1, to accurately monitor 
variations in this reliable microglial activation marker. However, as elucidated by the flow 
cytometry results (Figure 7 Figure 8), not all the LPS-stimulated microglia population become 
activated. Then, the use of a sorting cytometer would allow the exclusive analysis of the 
activated microglial population by techniques such as western blot or real-time polymerase 
chain reaction (qPCR). 
Additionally, results obtained using the yeast model strongly suggest that one of the 
mechanisms by which the digested raspberry polyphenolic fractions attenuate 
 
N9 microglial neuroinflammatory model Yeast model of inflammation 
 NO TNF-α O2
•- CD-40 Qualitative Quantitative 
R1 +++ ++ ++ ++ ++ +++ 
R2 +++ ++ ++ ++ +++ +++ 
R3 +++ + 0 + + + 
R4 +++ + 0 + ++ +++ 
R5 +++ +++ +++ +++ +++ +++ 
Extract 
Marker 
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neuroinflammation in microglia is through the repression of Ca2+-signaling pathways, and 
consequently the pro-inflammatory gene expression driven by NFAT. As previously referred, 
this is a key pathway that regulate the microglial activation by the secretion of pro-inflammatory 
cytokines such as TNF-α27. The use of the yeast model also strengthened R1, R2 and R5 as 
the fractions with higher potential to attenuate neuroinflammation. Conversely, the R3 fraction 
was confirmed to be the fraction with the lowest anti-inflammatory power. 
With the comparison between the results obtained with all the digested fractions and 
their chemical characterization, important aspects were highlighted. Firstly, the capacity in 
attenuating neuroinflammation does not seem to depend on the total phenols content. 
Additionally, two of the fractions that evidenced higher neuroinflammatory attenuation (R2 and 
R5) have the lowest concentrations, by far, in total flavonoids and anthocyanins. However, 
these fractions have relatively high concentrations in total ellagic acid conjugates.  
Ellagic acid and its conjugates may have a beneficial role in the attenuation of 
neuroinflammation147, 148. The opposite was demonstrated in the present work relatively to the 
anthocyanin content, since the fraction with the higher anthocyanin content (R4) exhibited low 
capacity to attenuate neuroinflammation. Moreover, R5 – the yellow raspberry, with nearly no 
anthocyanin content, strongly attenuated all the tested pro-inflammatory activation markers in 
microglia, as well as Crz1 activation in the yeast model of inflammation. Nevertheless, the 
synergistic effect can also be the key for the anti-inflammatory capacity promoted by these 
fractions, and not only the composition in a restrict group of polyphenols. 
Not less important is the fact that this study has been carried out with digested fractions 
produced by an in vitro digestion model, which is not always possible in similar studies. It is 
also important to emphasize the fact that the digested fractions were used at concentrations 
near the physiologic levels found in blood serum, accordingly with literature143. 
In the future, these fractions should be tested in other neuroinflammatory models, such 
as human microglia cell lines or primary microglial cells. It is equally necessary to understand 
if any neuroprotective effect also accompanies the neuroinflammatory attenuation promoted 
by these fractions, and if all together contribute for the prevention / regression of some of the 
neurodegenerative disorders such as Parkinson’s or Alzheimer’s diseases. 
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Attachment 1- Structures of major dietary polyphenols and the respective groups 
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Cultivar 
Total phenols 
(mg.100g-1 FDW) 
Total anthocyanins  
(LC-PDA) 
(mg.100g-1 FDW) 
Total flavonols 
(mg.100g-1 FDW) 
(from MS each peak) 
Total ellagic acid 
conj. (relative) 
(from MS each peak) 
Total 
ellagitannins 
(relative) 
R1  
(Glen Enrich IN) 
9602 596 13 20 2.4 
R2  
(0304F6 IN)  
3392 151 5 16 1.0 
R3  
(00123A7 IN) 
4412 323 28 12 1.3 
R4 
(Tulameen IN)  
5270 681 21 20 1.4 
R5  
(2J19 yellow 
raspberry IN)  
5851 3 8 18 1.6 
 
Attachment 2 – Table with the constitution in polyphenols found in each of the five quasi-isogenic raspberry 
cultivars.  
  
 
 
 
 
